Catalyst Dossier · compiled by CeliA 🧫
GSK plc (GSK)
Pharmaceutical Preparations · market cap $101.7B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-13 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
GSK plc is a British multinational pharmaceutical and biotechnology company with a market cap of approximately $101.7B and ~65,000 employees, operating across vaccines, specialty medicines, and general medicines. The company carries a broad late- and mid-stage pipeline spanning oncology, respiratory, infectious disease, and cardiovascular indications, with a cluster of Phase 2 readouts expected across H2 2026. Analyst consensus sits at hold, with a mean price target of ~$56.63 against a current price of ~$53.09, implying modest upside at consensus.
The catalyst path
- 2026-10-13 (est.)Phase 2 · Cobolimabimp 7/10
- 2026-10-14 (est.)Phase 2 · Momelotinibimp 7/10
- 2026-11-02 (est.)Phase 2 · Dostarlimabimp 7/10
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-28 (est.)Phase 2 · Niraparibimp 7/10
- 2026-12-31 (est.)Phase 2 · MMBimp 7/10
- 2027-01-12 (est.)Phase 2 · Adjuvanted RSVPreF3 vaccineimp 7/10
- 2027-01-26 (est.)Phase 3 · FF/UMEC/VIimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Fluoride | Phase 3 | Dental Caries |
| GSK2269557 DPI | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A. | Phase 2 | Hepatitis B |
| 62.5/25mcg | Phase 3 | Pulmonary Disease, Chronic Obstructive |
| Losmapimod 7.5 mg twice daily | Phase 3 | Acute Coronary Syndrome |
| RTS,S/AS01E | Phase 2 | Malaria |
| Combined Hepatitis A and B vaccine | Phase 3 | Hepatitis B |
| GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix) | Phase 3 | Infections, Meningococcal |
| SB-485232 | Phase 2 | Melanoma |
| Investigational MMRV(H)NS vaccine | Phase 2 | Measles; Mumps; Rubella; Chickenpox |
| 16448 | Phase 2 | Premature Ejaculation |
| Haemophilus influenzae type b- and meningococcal (vaccine) | Phase 3 | Haemophilus Influenzae Type b |
| FLU-QIV | Phase 3 | Respiratory Syncytial Virus Infections |
| 1278863A | Phase 2 | Kidney Disease |
| glyburide | Phase 3 | Diabetes Mellitus, Type 2 |
| Sulfonylurea | Phase 3 | Diabetes Mellitus |
| alosetron | Phase 3 | Irritable Colon |
| GBS Trivalent Vaccine | Phase 2 | Bacterial Infection Due to Streptococcus, Group B |
| GSK malaria vaccine 257049 Vaccine | Phase 2 | Malaria |
| GW869682 | Phase 2 | Obesity |
Price & technical context
3-month
-2.6%
6-month
-2.4%
12-month
+24.7%
52-wk range
$39.52–$61.18
vs 50-day MA
-0.6%
vs 200-day MA
-3.2%
Realized vol
27.2%
Max drawdown
-27.5%
Daily closes through 2026-09-22. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GSK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.